• Exosomal HMGB1 Drives Endothelial Injury in Lupus Nephritis

  2026-08-26

  This study identifies podocyte-derived exosomal HMGB1 as a mechanistic signal that promotes glomerular endothelial cell injury in lupus nephritis through TRIM27 upregulation. Its combined human, cellular, and mouse-model evidence shows how GW 4869 and cargo-specific interventions can help distinguish exosome-mediated podocyte–endothelial communication from downstream endothelial effects.

• Meropenem Workflows for Resistance Research

  2026-08-26

  Build reproducible Meropenem assays for susceptibility testing, time-kill analysis, resistance selection, and infection-model benchmarking. This guide connects PBP-directed bactericidal activity with practical controls for compound handling, exposure design, formulation comparisons, and troubleshooting.

• Dhcr7 Knockout Grass Carp Resists GCRV

  2026-08-25

  A 2026 Aquaculture Reports study used CRISPR/Cas9-mediated dhcr7 disruption to improve grass carp resistance to lethal GCRV-II infection. The work links sterol metabolism with Irf3-associated antiviral immunity while reporting preserved measured growth and muscle morphology, supporting Dhcr7 as an in vivo breeding target rather than only a cell-culture candidate.

• Hexetidine: Biofilm Age Changes the Answer

  2026-08-25

  Hexetidine (NSC-17764) behaves differently against suspended cells, newly attached bacteria, and mature biofilms. This article translates device-associated biofilm research into state-aware assay decisions for oral infection, antimicrobial testing, and translational study design.

• Meropenem: From PBP Biology to Resistance Strategy

  2026-08-24

  Meropenem is more than an ultra-broad-spectrum injectable antibiotic: it is a useful translational probe for connecting penicillin-binding protein biology, exposure-response design, resistance modeling, and formulation strategy. This thought-leadership article shows how to use Meropenem in Gram-negative and Gram-positive infection research, compare its mechanistic positioning with ceftolozane/tazobactam, and build preclinical models that generate interpretable rather than merely positive results.

• Antiseptics for Burns: Evidence and Research Implications

  2026-08-23

  The 2017 Cochrane review assessed antiseptic strategies for burn wounds and found that inconsistent, low-certainty evidence prevented confident conclusions about superiority for healing, infection control, or safety. Its main contribution is a structured comparison of heterogeneous topical interventions, offering practical guidance for interpreting burn-care studies and designing related antibacterial experiments.

• Vancomycin hydrochloride in Resistance Assays

  2026-08-22

  Use Vancomycin hydrochloride as a mechanism-defined control for Gram-positive bacteria inhibition, bacterial susceptibility testing, and resistance profiling. This workflow connects reproducible bench assays with infection-model design while showing how newer antimicrobial-peptide concepts can refine comparative experiments.

• AI-10-49 in CBFβ-SMMHC Leukemia Research

  2026-08-21

  AI-10-49 enables a mechanism-led workflow that connects CBFβ-SMMHC–RUNX1 dissociation with chromatin, transcriptional, and viability readouts. Its strongest use case is comparative acute myeloid leukemia research, where fusion-positive models can be distinguished from nonspecific cytotoxicity.

• Gamithromycin: Designing Better Assays

  2026-08-21

  Gamithromycin research is often interpreted through standard MIC values, yet serum can materially change macrolide potency. This article explains how to build more physiologically relevant assays while separating evidence from veterinary dosing and translational assumptions.

• Methicillin Sodium Salt: MSSA Workflow Guide

  2026-08-20

  Build reproducible MSSA susceptibility assays, resistance controls, and gram-positive infection models with Methicillin sodium salt. This guide translates a rigorously controlled antibiotic-trial framework into practical bench workflows while clearly separating validated product specifications from recommended assay starting points.

• Cefiderocol Activity Against Resistant Enterobacterales

  2026-08-20

  This European surveillance study directly compared cefiderocol with approved and developmental β-lactam/β-lactamase inhibitor combinations across 1,909 Enterobacterales isolates, including meropenem-resistant organisms. Cefiderocol retained high in vitro activity against many difficult phenotypes, while genomic analysis linked cefiderocol resistance to combined iron-uptake, carbapenemase, and target-site alterations.

• Faropenem Transport via Renal Npt1

  2026-08-19

  The reference study identified mouse Npt1 as a renal luminal transporter capable of exporting faropenem, revealing a molecular component of penem antibiotic secretion that was poorly defined at the time. Using radiolabeled uptake and efflux assays in Xenopus oocytes, the authors showed chloride-sensitive, sodium-independent transport and competitive inhibition by several anionic β-lactams and organic anions.

• D-N-Acetylgalactosamine Protocol Guide

  2026-08-18

  D-N-Acetylgalactosamine (SKU B7904) provides a defined, water-soluble reagent for workflows examining glycoprotein constituents and brain heteropolysaccharides. It is suitable for aqueous or compatible DMSO preparations, but should not be selected for ethanol-based protocols or long-term storage of prepared solutions.

• Mupirocin and Novobiocin in Resistant Staphylococci

  2026-08-18

  Fulham and colleagues evaluated mupirocin and novobiocin against meticillin-susceptible and meticillin-resistant staphylococci recovered from healthy dogs and dogs with superficial pyoderma. The study’s practical contribution is its side-by-side comparison of resistance phenotype, clinical context, and susceptibility results, highlighting novobiocin’s reduced activity against some resistant isolates and the need for isolate-specific testing.

• Cefazedone PK/PD: From MIC to Clinical Meaning

  2026-08-17

  Cefazedone (Refosporen) connects PBP-directed cell-wall inhibition with clinically relevant MIC and fT>MIC interpretation. This evidence-led guide shows how to design antibacterial testing in vitro and translate results into rational treatment of community-acquired pneumonia research.

456 records 7/31 page Previous Next First page 上5页 678910 下5页 Last page